Needham has recently reiterated Viridian Therapeutics Inc (VRDN) stock to Buy rating, as announced on September 11, 2024, according to Finviz. Earlier, on June 11, 2024, Wolfe Research had initiated the stock to Outperform, setting a price target of $29. Goldman also initiated Buy rating with a price target of $23. Additionally, Ladenburg Thalmann reduced Neutral rating on May 9, 2024. B. Riley Securities analysts, in their report published on May 9, 2024, also reduced Neutral rating and set a price target of $25 for Viridian Therapeutics Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
Viridian Therapeutics Inc (VRDN) Stock Trading Recap
On Monday, Viridian Therapeutics Inc (VRDN) stock saw a decline, ending the day at $22.75 which represents a decrease of $-0.58 or -2.49% from the prior close of $23.33. The stock opened at $22.75 and touched a low of $22.14 during the day, reaching a high of $23.53. The volume of shares traded was 0.87 million falling short of the average volume of 1.50 million.
VRDN Stock Performance and Moving Averages
In recent trading, Viridian Therapeutics Inc (VRDN) stock price has shown some volatility, fluctuating 7.72% over the last five trades and 51.67% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 31.81%, and it has gained 72.22% in the previous three months. Currently, VRDN is trading at 17.96%, 33.90%, and 35.83% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, VRDN, a Healthcare sector stock, is trading -5.91% below its 52-week high but remains 108.24% above its 52-week low. The Average True Range (ATR) (14 days) of 1.49 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Viridian Therapeutics Inc’s Profitability and Valuation Ratios
Viridian Therapeutics Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -87078.82% and a profit margin of -79185.76%, with a gross margin of 31.81%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Viridian Therapeutics Inc’s market capitalization stands at $1.74 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 5990.31, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 3.79, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 13.04% of Viridian Therapeutics Inc (VRDN)’s shares, while financial institutions hold 82.45%.
